Work

Data from Phase IIA Trial Testing Erlotinib as an Intervention against Intraductal Pancreatic Mucinous Neoplasms

Year: 2023

Type: other

Abstract: Intraductal papillary mucinous neoplasms (IPMN) are a distinct type of precursor lesions that cause about 5% of pancreatic adenocarcinoma (1, 2). Four-year survival rates of 40% to 75% are reported (3–7). There is currently no chemotherapy specifically approved for treating IPMNs. The number of IPMN cases has significantly increased over the last decade (8). Cancer Prev Res; 4(4); 512–3. ©2011 AACR.

DOI: 10.1158/1940-6207.c.6543967.v1

Authors: Steven Lipkin, John Lee, David Imagawa, Stephen M. Hewitt, Chris Tucker, Jason A. Zell, Vanessa Wong, Angela Garcia, Rachel Gonzalez, Gary Della Zanna, Ellen Richmond, L.M. Rodriguez, M Bigg, F Schnoll-Sussmans, Frank Meyskens

Language: English

Topic: Pancreatic and Hepatic Oncology Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4392721987

Cites:

Cited by:

Related to: 10